Tag: Food and Drug Administration
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MORE
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE
Breaking News: FDA Approves Treatment for pNET Patients
For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients! The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients. This is a milestone for the carcinoid/NET…
READ MORE
Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting
Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORE
Carcinoid & Neuroendocrine Tumor Patients Invited to FDA Public Hearing
For carcinoid and neuroendocrine tumor patients who would like their voices to be heard regarding the Food and Drug Administration’s (FDA) regulation of drugs, biologics, and devices for the diagnosis and treatment of rare diseases, you are invited…
READ MORE
